Effect and Efficacy Analysis of Modified Chishizhi Yuyuliang Tang in Patients with Cirrhosis Ascites (Spleen-Kidney-Yang Deficiency)

GAN Xia; ZHAO Xin-fang; LIN Hong; ZHOU Yun

doi:10.13422/j.cnki.syfjx.2016060172

您当前的位置：

首页 >

文章列表页 >

Effect and Efficacy Analysis of Modified Chishizhi Yuyuliang Tang in Patients with Cirrhosis Ascites (Spleen-Kidney-Yang Deficiency)

更新时间：2024-01-04

- Effect and Efficacy Analysis of Modified Chishizhi Yuyuliang Tang in Patients with Cirrhosis Ascites (Spleen-Kidney-Yang Deficiency)
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 22, Issue 6, Pages: 172-176(2016)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2016060172
  CLC： R259
- Published：2016
- 稿件说明：
移动端阅览
GAN Xia, ZHAO Xin-fang, LIN Hong, et al. Effect and Efficacy Analysis of Modified Chishizhi Yuyuliang Tang in Patients with Cirrhosis Ascites (Spleen-Kidney-Yang Deficiency)[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2016, 22(6): 172-176.
DOI：

GAN Xia, ZHAO Xin-fang, LIN Hong, et al. Effect and Efficacy Analysis of Modified Chishizhi Yuyuliang Tang in Patients with Cirrhosis Ascites (Spleen-Kidney-Yang Deficiency)[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2016, 22(6): 172-176. DOI： 10.13422/j.cnki.syfjx.2016060172.

摘要

目的: 探讨加味赤石脂禹余粮汤治疗肝硬化腹水脾肾阳虚证的临床疗效及对腹水中葡萄糖(GLU)和乳酸脱氢酶(LDH)水平以及血清腹水白蛋白梯度(SAAG)的影响。方法: 共选入脾肾阳虚证肝硬化腹水患者104例

随机按照入院先后顺序分为对照组和治疗组各52例。两组均参照《肝硬化腹水的中西医结合诊疗共识意见》标准给予限钠、护肝和利尿治疗;对照组给予恩替卡韦片口服

0.5 mg/次

1次/d。治疗组在对照组用药的基础上给予加味赤石脂禹余粮汤治疗

1剂/d

常规水煎煮

分早晚2次内服。两组患者均治疗4周。比较两组患者治疗前后中医临床症状评分;采取B超检测两组患者门静脉与脾静脉主干宽度和腹水深度;检测两组患者腹水中LDH和GLU水平;比较两组患者治疗前后SAAG。结果: 治疗组治疗后中医临床症状评分均明显低于对照组(P<0.01);治疗组临床总有效率为88.46%

对照组为67.31%

治疗组高于对照组(P<0.05);治疗组治疗后门静脉与脾静脉主干宽度和腹水深度均明显低于对照组(P<0.05

P<0.01);治疗后治疗组患者腹水LDH和GLU水平以及SAAG均明显低于对照组

比较差异均有统计学意义(P<0.01)。结论: 加味赤石脂禹余粮汤联合恩替卡韦片治疗肝硬化腹水脾肾阳虚证可明显改善患者中医临床症状

改善肝硬化门静脉高压

提高腹水临床治疗效果

可降低患者腹水中LDH和GLU水平以及SAAG。

Abstract

Objective: To investigate the clinical efficacy of Modified Chishizhi Yuyuliang Tang for cirrhosis ascites of spleen-kidney-yang deficiency and its effect on glucose (GLU) and lactate dehydrogenase (LDH) levels in ascitic fluid and serum-ascites albumin gradient (SAAG). Method: One hundred and four patients with cirrhosis ascites of spleen-kidney-yang deficiency were randomly divided into control group (52 cases) and treatment group (52 cases) with digital table method. By referring to the treatment methods in 'A Consensus Opinion on The Diagnosis and Treatment of Cirrhosis Ascites in The Traditional Chinese and Western Medicine'

patients of both groups were treated with therapy of sodium restriction

liver protection and diuresis. Patients of control group were treated with entecavir tablets (0.5 mg/time

qd) by orally taking. Patients of treatment group were also treated with Modified Chishizhi Yuyuliang Tang based on the treatment in control group (1 dose/d in form of water decoction

bid). The treatment course was 4 weeks for both groups. The traditional Chinese medicine (TCM) symptom scores in both groups were compared before and after treatment.The width of the trunk of vena portae and vena lienalis and the depth of ascites were detected by B ultrasound. LDH and GLU levels in ascites were detected for both groups. Levels of SAAG were compared in two groups before and after treatment. Result: The TCM symptom scores in treatment group were significantly lower than those in control group after treatment (P<0.01). The total efficacy of treatment group was 88.46%

significantly higher than 67.31% in control group

with statistically significant difference (P<0.05). Compared with control group

the width of the trunk of vena portae and vena lienalis and the depth of ascites were significantly lower in treatment group after treatment (P<0.05

P<0.01). Levels of LDH

GLU in ascites and SAAG were significantly lower in the treatment group than those in control group after treatment

with statistically significant differences (P<0.01). Conclusion: Modified Chishizhi Yuyuliang Tang combined with entecavir for cirrhosis ascites of spleen-kidney-yang deficiency could evidently improve the TCM symptoms

cirrhotic portal hypertension

clinical therapeutic effects of ascitic fluid and reduce levels of LDH

GLU in ascites and SAAG level.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Staged Efficacy of Qijia Rougan Prescription Combined with Entecavir for Chronic Hepatitis B-related Hepatic Fibrosis with Qi Deficiency and Collateral Stasis Syndrome Based on "Zhu Ke Jiao" Theory

Qiangshen Yugan Decoction Combined Entecavir Treatment for Chronic Hepatitis B 40 Cases

Curative Effect and Quality of Life of Chronic Hepatitis B Patients with Liver Fibrosis with Syndromes of Liver Depression, Spleen Deficiency and Blood Stasis Obstruction Treated with Ruangan Huaxian Decoction Combined with Entecavir

Anti-HBV Effect and Mechanism of Sophora Alkaloids Combined with Entecavir

Differential Analysis of Clinical Features and Outcomes Between Syndrome of Combined Phlegm and Stasis and Syndrome of Dampness-heat Internal Accumulation in Hepatic Wilson's Disease

Related Author

FENG Quansheng

LI Baixue

WANG Xin

LIU Jibin

WEN Li

JIANG Cen

WU Wenjun

WANG Dong

Related Institution

School of Basic Medical Sciences， Chengdu University of Traditional Chinese Medicine（TCM）

Chongqing TCM Hospital

Public Health Clinical Center of Chengdu

Hospital of Chengdu University of TCM

Meishan TCM Hospital

AI问答

Address：No. 16, Nanxiaojie, Dongzhimennei, Beijing Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰